



Express Mail. No.: EV 452 777 175 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	BRÖGMANN, Bianca et al.	Confirmation No.:	1884
Serial No.:	10/510,674	Art Unit:	1614
Filing Date:	May 23, 2005	Examiner:	To Be Assigned
Title:	PHARMACEUTICAL PREPARATION CONTAINING OXYCODONE AND NALOXONE	Attorney Docket No:	6750-308-999
		(CAM No.:	305158-999301)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

Enclosures accompanying this Information Disclosure Statement are the following:

1. A Substitute Form 1449/PTO entitled Information Disclosure Statement by Applicant listing References **A01-A04**, **B01-B07** and **C01-C07**;
2. Copies of References **B01-B07** and **C01-C07**.

Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of References **A01-A04**, which are United States patent documents, are not being submitted unless required by the Office.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of a first Office Action on the merits. Therefore, no fee is believed to be due for this Information Disclosure Statement. If any fee is believed to be due, however, the Commissioner is hereby authorized to charge any such fees that may be due to Jones Day Deposit Account No. 50-3013.

No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made. 37 C.F.R. §§1.97(g) and (h).

Date: March 2, 2006

Respectfully submitted,

Gidon Stern / by Ian Scott Reg. No. 44,327
27,469
Gidon D. Stern
Reg. No.
JONES DAY
222 East 41st Street
New York, N.Y. 10017-6702
212-326-3939

Enclosures



APPLICATION NO.
10/510,674

ART UNIT:	CONF. NO.:
1614	1884

EXAMINER'S INITIALS*		DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	3,773,955	11/20/1973	Pachter et al.	
	A02	3,966,040	06/29/1976	Pachter et al.	
	A03	4,457,933	07/03/1984	Gordon et al.	
	A04	4,582,835	04/05/1986	Lewis et al.	

EXAMINER'S INITIALS*		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
	B01	EP 0 352 361	01/31/1990	The Rockefeller University			
	B02	DE 43 25 465	02/02/1995	Zens et al. (in German)		X	
	B03	GB 1 390 772	04/16/1975	Endo Lab			
	B04	RU 98102450	07/12/1996	(in Russian, w/ English abstract)			
	B05	WO 99/32119	07/01/1999	Euro Celtique S.A.			
	B06	WO 99/32120	07/01/1999	Euro Celtique S.A.			
	B07	WO 03/007802	01/30/2003	Euro Celtique S.A.			

EXAMINER'S INITIALS*		
	C01	Cherry et al., "Opioids in pain therapy," The Frankfurt Consensus, STK - Special Issue 2001 Article 2 (3 pages) (in German, w/ English translation)
	C02	Ebell et al., "The management of pain in cancer patients," Supportive Measures in Oncology, Jehn et al., eds., 1994, vol. 3 (in German, w/ English translation)
	C03	Forth et al., General and Special Pharmacology and Toxicology, 7th rev. ed., 1996, pp. 207-217 (in German, w/ English translation)
	C04	Neuenschwander et al., Palliative Medicine At A Glance, 1999 (whole book)
	C05	Oxygesic® Product Information, 1997-2001 (in German, w/ English translation)
	C06	Valoron® Product Information, 1997-2001 (in German, w/ English translation)
	C07	Zech et al., "Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study," Pain, 1995 Oct;63(1):65-76

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.